A phase I clinical trial of interferon‐beta gene therapy for high‐grade glioma: novel findings from gene expression profiling and autopsy
A phase I clinical trial of interferon‐beta gene therapy for high‐grade glioma: novel findings from gene expression profiling and autopsy
复制标题
DOI：
10.1002/jgm.1160
复制
发表时间：
2008-04
期刊：
影响因子：
--
通讯作者：
T. Wakabayashi;A. Natsume;Y. Hashizume;M. Fujii;M. Mizuno;J. Yoshida
中科院分区：
文献类型：
--
作者：
T. Wakabayashi;A. Natsume;Y. Hashizume;M. Fujii;M. Mizuno;J. Yoshida
高级别胶质瘤是高致死性肿瘤，约占所有颅内肿瘤的20%。已发现阳离子脂质体介导的干扰素-β（IFN-β）基因转移可诱导实验性胶质瘤消退。我们之前进行了一项试点临床试验，以评估这种IFN-β基因治疗在5名高级别胶质瘤患者中的安全性和有效性。两名患者显示减少超过50%，而其他患者在治疗开始后10周病情稳定。
High‐grade gliomas are highly lethal neoplasms representing approximately 20% of all intracranial tumors. Cationic liposome‐mediated interferon‐beta (IFN‐β) gene transfer has been found to induce regression of experimental glioma. We have previously performed a pilot clinical trial to evaluate the safety and effectiveness of this IFN‐β gene therapy in five patients with high‐grade glioma. Two patients showed more than 50% reduction while others had stable disease 10 weeks after treatment initiation.